Q-omics provides the consensus-scored NTSR2 profile across patient tissues and cancer cell-line models. NTSR2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NTSR2 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, NTSR2 RNA expression shows 12,615 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where NTSR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTSR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTSR2 survival associations across molecular data types. NTSR2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTSR2 RNA expression–survival associations across cancer types. High NTSR2 expression shows unfavorable associations in UCEC, THCA, KIRP and COAD, but favorable associations in HNSC and MESO. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for NTSR2 RNA expression.
This table summarizes NTSR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NTSR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTSR2 shows lower tumor expression in STAD and higher tumor expression in KIRC, LUSC, COAD and LUAD. The KIRC box plot shows higher NTSR2 RNA expression in tumor versus normal tissue (log2 FC = +0.021, t-test p = .011).
This table shows molecular features associated with NTSR2 in patient tissues and cancer cell lines. In patient samples, NTSR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NTSR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
